Merit Medical Systems (NASDAQ:MMSI) Reports Bullish Q2 CY2026, Stock Soars
Medical device company Merit Medical Systems (NASDAQ: MMSI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates. Is now the time to buy Merit Medical Systems? Find out by accessing our full research report, it’s free.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the Q2 revenue and adjusted EPS beats versus expectations, plus full-year revenue guidance at the midpoint coming in above analysts’ estimates. The main offset is the YoY decline in adjusted operating margin during the quarter.
Market read
A straightforward earnings-and-guidance beat with an immediate post-report stock pop, tempered by margin contraction in the quarter.
What to watch
Organic revenue growth is highlighted, but the article also attributes results to excluding a strategic divestiture and notes FX/acquisition effects; traders should separate underlying demand from one-off portfolio impacts.
Background
Merit Medical Systems is a medical device manufacturer focused on minimally invasive procedures across cardiology, radiology, oncology, critical care, and endoscopy.
Ticker impact
Merit Medical Systems reported Q2 CY2026 revenue of $418.8M (+9.5% YoY) and adjusted EPS of $1.19, beating estimates, and guided FY revenue to $1.64B midpoint.
Bullish bias for the next sessions, with follow-through dependent on whether investors focus on the beat and guidance versus the YoY adjusted operating margin decline.
The article provides concrete earnings and guidance numbers and notes the stock jumped 5.1% immediately after reporting, indicating a market repricing; however, it also flags a quarterly adjusted operating margin contraction, which can temper enthusiasm.
Market effects
Positive read-through for medical device demand and procedure-linked device utilization, but limited to one issuer’s results.
No specific regional demand or regulatory changes cited.
No direct global macro or cross-border policy impacts mentioned beyond organic growth and currency/ divestiture effects.
Counterpoint
The quarter’s adjusted operating margin fell 3.6 percentage points YoY, suggesting cost pressure or mix headwinds that could cap multiple expansion despite the top-line beat.
Key entities
- companyMerit Medical Systems
NASDAQ-listed medical device company reporting Q2 CY2026 results and full-year revenue guidance.
- executiveMartha G. Aronson
President and CEO quoted on Q2 performance being driven by organic, constant currency revenue growth excluding divestiture impact.
